KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Invested Capital (2016 - 2025)

Gilead Sciences (GILD) has disclosed Invested Capital for 17 consecutive years, with $24.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 45.74% year-over-year to $24.9 billion, compared with a TTM value of $77.6 billion through Dec 2025, up 68.78%, and an annual FY2025 reading of $24.9 billion, down 45.74% over the prior year.
  • Invested Capital was $24.9 billion for Q4 2025 at Gilead Sciences, roughly flat from $24.9 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $49.9 billion in Q2 2021 and bottomed at $24.9 billion in Q4 2025.
  • Average Invested Capital over 5 years is $42.9 billion, with a median of $46.2 billion recorded in 2022.
  • The sharpest move saw Invested Capital soared 150.98% in 2021, then plummeted 45.74% in 2025.
  • Year by year, Invested Capital stood at $47.8 billion in 2021, then decreased by 2.77% to $46.4 billion in 2022, then increased by 2.8% to $47.7 billion in 2023, then dropped by 3.73% to $46.0 billion in 2024, then tumbled by 45.74% to $24.9 billion in 2025.
  • Business Quant data shows Invested Capital for GILD at $24.9 billion in Q4 2025, $24.9 billion in Q3 2025, and $44.5 billion in Q2 2025.